---
schema_version: "secwatch.filing_event.v1"
accession: "0001640334-25-000428"
form_type: "8-K"
ticker: "BDPT"
cik: "0001575142"
company_name: "BIOADAPTIVES, INC."
filed_at: "2025-03-18T23:59:59+00:00"
generated_at: "2026-05-24T13:39:44.381817+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# BioAdaptives' Zeranovia weight loss product shows 5-7 lbs/week loss in dosage trial

## Summary
- Participants lost 5–7 pounds per week in Zeranovia dosage trial.
- Minimal side effects: mild GI discomfort manageable by increasing water intake or adjusting dosage.
- All trial subjects requested to proceed to next phase, indicating high satisfaction.
- Company advancing to dosage adjustments for next-stage clinical trials.

## SEC filing metadata
- accession: 0001640334-25-000428
- form_type: 8-K
- ticker: BDPT
- cik: 0001575142
- company_name: BIOADAPTIVES, INC.
- filed_at: 2025-03-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1575142/000164033425000428/0001640334-25-000428-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1575142/000164033425000428/bdpt_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001640334-25-000428
- JSON: https://secwatch.observer/filing/0001640334-25-000428.json
- Plain text: https://secwatch.observer/filing/0001640334-25-000428.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.